In the throes of a raging virus pandemic, one small startup is stepping up. First Stage Investor portfolio company 20/20 GeneSystems is gearing up to provide COVID-19 tests.
As you may remember, 20/20’s main business (and why we recommended you invest in it in the first place) is layering artificial intelligence over the top of blood tests to help detect cancer in its earliest stages.
It’s still doing that. But due to the pressing needs of the novel coronavirus pandemic, 20/20 is moving quickly to bring a rapid COVID-19 field test to the market in the U.S.
The company has two goals. It wants to play a critical role in fixing the nation’s shortage of COVID-19 tests. And it wants to capture at least 5% of the COVID-19 testing market.
This is terrific news for our country. We desperately need the test that 20/20 is hoping to bring to market as soon as next week. It’s also good news for investors. StartEngine is in the middle of raising funds. And right now, you can buy its shares at a price that was determined before the coronavirus appeared. In other words, you’d be buying into an explosive growth opportunity at a heavily discounted price.
This is such an outstanding opportunity that we thought you should hear more about it from the founder himself, Jonathan Cohen. Early Investing, along with KingsCrowd, will be hosting an exclusive livestreaming webinar with Jonathan and his lieutenants this Thursday, April 2, from 3 p.m. to 4 p.m. ET (noon to 1 p.m. on the West Coast). Just click here to register.
Jonathan will be answering these questions (among others)…
- What exactly is the rapid blood test 20/20’s making available in the U.S.?
- What does it do that current swab tests don’t do?
- How big is the market for these tests?
- Who will be 20/20’s biggest customers?
- How can you invest in 20/20’s current raise?
The webinar will include a Q&A session, where you can ask Jonathan and his lieutenants anything you want.
If you want to learn more about this new test and unique investment opportunity, just click here to register. We’ll also send you a reminder the day before.
20/20 GeneSystems reminds us of how startups are constantly on the lookout for game-changing technology and how they – unlike larger legacy companies – can turn that technology into enriching enterprises for society, themselves and their investors.